A Collaborative View For Industry Support - Chewing It Over with Jim Carr | Eos Active

eosactive.co.uk

In this episode of Chewing It Over, Jack speaks with Jim Carr from EOS Active about a part of MSK practice that often gets overlooked or handled poorly: the relationship between products, pathways, branding, and patient communication.

Although EOS Active technically sells products into the MSK space, Jim is clear that he does not want to be seen as simply “selling injections.” Instead, he argues that products only make sense when they are nested within a wider, well-reasoned patient pathway. An injection, brace, cryotherapy device, or sleeve is not the story in itself; it is only one possible component of a longer management process shaped by rehabilitation, education, timing, and patient context.

A major theme of the conversation is that clinics often inherit their marketing language from manufacturers without fully realising it. Glossy flyers, miracle-style testimonials, and product-led messaging can slowly become part of a clinic’s identity, even if they do not reflect how that clinic actually wants to practise. Jim’s answer is to help clinics present information in a more neutral, patient-centred way that supports trust rather than hype.

The discussion also explores why Jim feels unusually aligned with private clinics. He sees parallels between building a distribution business and building a clinical service: both require strategy, long-term thinking, and careful management of brand and reputation. Rather than pushing the newest thing, he prefers established, sensible options that fit real-world practice.

Overall, this episode is about thinking beyond transactions. It asks clinics to be more intentional about what they communicate, how they communicate it, and how commercial choices shape the care experience patients receive.

Cingal® as a multi-joint injection is now EU MDR certified.

The certification includes expanded indications for multiple synovial joints, including the knee, hip, shoulder and ankle, supporting broader clinical application.

As part of the MDR transition, the manufacturer is completing the final administrative steps to ensure update IFUs and supporting documentation are available in line with regulatory requirements. Further information will be shared in due course. Eos active as te UK partner are preparing updated marterials allowing you to communicate appropriatley with patients in clinic and can answer questions and quiries about this recent update.